October 29, 2020
Daiichi Sankyo and AstraZeneca said on October 28 that the US FDA has accepted for priority review their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for an additional indication of certain patients with gastric cancer. Their application seeks the drug’s...read more